Belite Bio
BLTE158.6100.82% ( -1.310 )
Belite Bio (BLTE)
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical n...
- Open
- 159.630
- High
- 161.000
- Low
- 155.180
- Prev. Close
- 159.920
- Volume
- 159.28K
- Turnover
- 25.17M
- Avg Price
- 158.024
- Bid/Ask Ratio
- --
- Amplitude
- 3.64%
- 52wk High
- 200.000
- Volume Ratio
- 0.98
- Turnover Ratio
- 0.83%
Belite Bio Analyst Rating
View MoreForecast & Rating
Jul 27, 2026Price forecast
$210.5032.72%
Forecast & RatingStrong buy
8analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · Jul 30 at 04:14 AM
The Uncategorized Fringes: What 9 Misfit Stocks Tell Us About the 2026 Market
- Market Beat · Jul 22 at 04:02 PM
Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases
- Market Beat · Jul 22 at 10:00 AM
Belite Bio (NASDAQ:BLTE) Shares Gap Up - Should You Buy?
- benzinga_article · Jul 20 at 12:35 PM
Why Is Belite Bio Stock Gaining Monday?
- PUBT · Jul 20 at 07:03 AM
Belite Bio completes FDA filing for tinlarebant in Stargardt disease type 1
- PUBT · Jul 15 at 07:03 AM
Belite Bio joins H.C. Wainwright ophthalmology virtual conference panel July 22
